MAIA Biotechnology, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a fourth-quarter-only report. MAIA is a clinical-stage biotechnology company with no approved products and no product revenue.
Business context and development
MAIA’s lead candidate, THIO (6-thio-dG), is an investigational telomere-targeting cancer therapy intended to prime tumors for subsequent immune-checkpoint treatment. The lead program, THIO-101, is a Phase 2 study in advanced non-small cell lung cancer (NSCLC), sequencing THIO with Regeneron’s cemiplimab. The trial was underway in Australia; Hungary, Poland, and Bulgaria approved implementation in December 2022. The filing reports that the first European patients were dosed in March 2023, after year-end.
MAIA completed its IPO in August 2022, selling 2.3 million shares at $5 per share. It reported net proceeds of approximately $9.1 million after cash issuance costs. It also holds orphan drug designations for THIO in hepatocellular carcinoma and small-cell lung cancer. Its second-generation telomere-targeting program remains early-stage.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $8.93 million | $3.50 million |
| General and administrative expense | $6.14 million | $4.29 million |
| Total operating expenses | $16.18 million | $7.79 million |
| Net loss | $15.77 million | $12.58 million |
| Net loss attributable to MAIA shareholders | $16.22 million | $12.50 million |
| Basic and diluted loss per share | $1.75 | $2.37 |
| Net cash used in operating activities | $11.66 million | $4.12 million |
At December 31, 2022, cash was $10.95 million, working capital was $8.54 million, total assets were $12.02 million, and total stockholders’ equity was $8.51 million. Current liabilities were $3.27 million; total liabilities were $3.51 million, including a $245,000 warrant liability. No convertible notes were outstanding at year-end. Profit margins are not meaningful because the company had no revenue.
Financing cash flows were $12.04 million in 2022, primarily reflecting IPO proceeds, equity financing, and warrant and option exercises, offset by offering costs. Cash increased by $377,000 over the year. Management and the auditor state that recurring losses, negative operating cash flows, and the need for additional funding raise substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
Material changes versus 2021
- R&D expense increased 155%, primarily due to clinical-trial startup, preclinical research, and higher payroll and headcount.
- G&A expense increased 43%, reflecting public-company infrastructure, staffing, and professional fees.
- Operating cash use rose to $11.66 million from $4.12 million; cash remained roughly level because of financing.
- Net loss increased by $3.19 million. The 2022 loss included $1.10 million of ratchet-share expense and a $450,578 deemed dividend from warrant modifications. The 2021 comparison included significant convertible-note extinguishment and fair-value expenses.
- Loss per share narrowed despite the higher shareholder-attributable loss, with weighted-average shares increasing to 9.28 million from 5.28 million.
Outlook, risks, and unusual items
- At the time of the filing, MAIA planned to submit a U.S. IND in the first half of 2023 and begin U.S. enrollment in the second half of 2023. It described a possible accelerated-approval request in late 2024, contingent on clinical results and FDA agreement; neither approval nor timing is assured.
- The company planned a Phase 2 study in multiple solid-tumor indications in the fourth quarter of 2023. These are forward-looking plans, not achieved milestones.
- Clinical results, enrollment, regulatory requirements, manufacturing capacity, and access to additional capital are key uncertainties. THIO’s proposed effects are supported by preclinical work; its efficacy and safety in MAIA’s current clinical program remain to be established.
- MAIA depends on third-party manufacturers and trial service providers, and its THIO-101 arrangement gives Regeneron development exclusivity with PD-1 inhibitors for NSCLC during the study period. Regeneron supplies cemiplimab at no cost under the agreement.
- The company reported material weaknesses in financial-reporting controls, including inadequate segregation of duties and controls over complex transactions. Disclosure controls were judged ineffective at year-end; remediation was ongoing, including hiring a Corporate Controller and using outside accounting advisers.
- The 2022 financial statements received an unqualified audit opinion, with a separate going-concern emphasis. The filing also describes a change in auditor between the 2021 and 2022 audits.
- Equity financing may dilute existing holders. The filing reports 6.55 million outstanding stock options and 796,985 warrants at year-end, in addition to potential future financing needs.
Most important facts for investors to verify
- Whether available cash and subsequent financing are sufficient to fund operations and clinical programs, given the explicit going-concern warning and 2022 operating cash use.
- THIO-101 enrollment, safety, efficacy, dose selection, and the timing and requirements for a U.S. IND and expansion.
- Whether FDA feedback, trial design, and data can support any accelerated-approval strategy or will require additional or larger studies.
- Progress in remediating material weaknesses and the reliability of future financial reporting.
- Potential dilution and cash costs from future equity or debt financing, options, warrants, and contractual license obligations to UTSW.
- The filing contains differing IPO cost/proceeds presentations in its narrative and equity statement; investors should reconcile these figures to the audited statements and notes.